The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

As she prepares to change medications for her MS, columnist Leigh Anne Nelson explores the U.S. government’s registry on ...

Thousands of Australians battling a debilitating form of multiple sclerosis have been granted a reprieve, as a groundbreaking ...

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

An experimental stem cell therapy proved effective and safe in patients with a relapsing form of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, new research ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase II ...

CombiRx is a randomized clinical trial to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in ...

Background and Objective: During the last decade, several agents have proven to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS), for example interferon-β (IFNβ) and ...

A dramatic price plunge has put a world-class therapy within reach, offering new freedom and hope for thousands of Australians.

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...

A 49-year-old man with a long history of relapsing-remitting multiple sclerosis presents to the clinic for a routine follow-up visit. The patient was initially treated with glatiramer acetate ...